Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph Ib trial

被引：2
|
作者：
Pohlmann, Paula R. [1 ]
Diamond, Jennifer R. [2 ]
Hamilton, Erika [3 ,4 ]
Tolaney, Sara M. [5 ]
Zhang, Wei [6 ]
Iizuka, Koho [6 ]
Foster, Paul [6 ]
Molinero, Luciana [6 ]
Funke, Roel [6 ]
Adams, Sylvia [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] NYU, Langone Med Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT028
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
    Adams, Sylvia
    Diamond, Jennifer Robinson
    Hamilton, Erika Paige
    Pohlmann, Paula Raffin
    Tolaney, Sara M.
    Molinero, Luciana
    He, Xian
    Waterkamp, Daniel
    Funke, Roel Peter
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC).
    Molinero, Luciana
    Emens, Leisha A.
    Goldstein, Leonard D.
    Abbas, Alexander R.
    Koeppen, Hartmut
    Rugo, Hope S.
    Adams, Sylvia
    Chui, Stephen Y.
    Schmid, Peter
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] 12-month uptake of PD-L1 testing and atezolizumab (atezo) plus nab-paclitaxel (nab-pac) treatment in metastatic triple-negative breast cancer (mTNBC) following accelerated FDA-approval in the United States.
    Emens, Leisha A.
    Craggs, Christopher
    Debiasi, Marcio
    Kent, Matthew
    Luhn, Patricia
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    O'Sullivan, Hazel
    Collins, Dearbhaile
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 986 - 986
  • [5] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    Schmid, P.
    Adams, S.
    Rugo, H. S.
    Schneeweiss, A.
    Barrios, C. H.
    Iwata, H.
    Dieras, V.
    Hegg, R.
    Im, S. -A.
    Wright, G. Shaw
    Henschel, V.
    Molinero, L.
    Chui, S. Y.
    Funke, R.
    Husain, A.
    Winer, E. P.
    Loi, S.
    Emens, L. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22): : 2108 - 2121
  • [6] PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
    Kolbin, A.
    Velum, I
    Balykina, Y.
    Proskurin, M.
    VALUE IN HEALTH, 2019, 22 : S510 - S510
  • [7] A randomized phase II study of nab-paclitaxel plus durvalumab plus neoantigen vaccine versus nab-paclitaxel plus durvalumab in metastatic triple-negative breast cancer (mTNBC).
    Hernandez-Aya, Leonel Fernando
    Gao, Feng
    Goedegebuure, Peter S.
    Ma, Cynthia X.
    Ademuyiwa, Foluso Olabisi
    Park, Haeseong
    Peterson, Lindsay Leuthen
    Bagegni, Nusayba Ali
    Bose, Ron
    Gillanders, William E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer REPLY
    Schmid, Peter
    Chui, Stephen Y.
    Emens, Leisha A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 987 - 988
  • [9] The tumor microenvironment (TME) and atezolizumab plus nab-paclitaxel (A plus nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
    Emens, Leisha A.
    Goldstein, Leonard D.
    Schmid, Peter
    Rugo, Hope S.
    Adams, Sylvia
    Barrios, Carlos H.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Chang, Ching-Wei
    Koeppen, Hartmut
    Chui, Stephen Y.
    Loi, Sherene
    Molinero, Luciana
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer
    Li, Jiahao
    Zhang, Tiantian
    Lu, Peiyao
    Zhao, Jianfu
    Chen, Lin
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (10) : 705 - 713
12345